RTW INVESTMENTS, LP - MOONLAKE IMMUNOTHERAPEUTICS ownership

MOONLAKE IMMUNOTHERAPEUTICS's ticker is and the CUSIP is 61559X104. A total of 24 filers reported holding MOONLAKE IMMUNOTHERAPEUTICS in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.5%.

Quarter-by-quarter ownership
RTW INVESTMENTS, LP ownership history of MOONLAKE IMMUNOTHERAPEUTICS
ValueSharesWeighting
Q3 2023$28,500,000
+11.8%
500,0000.0%0.60%
+23.9%
Q2 2023$25,500,000
+138.4%
500,0000.0%0.48%
+117.5%
Q1 2023$10,695,000
+103.7%
500,0000.0%0.22%
+108.4%
Q4 2022$5,250,000
+35.3%
500,0000.0%0.11%
+20.2%
Q3 2022$3,880,000
+47.8%
500,0000.0%0.09%
+30.9%
Q2 2022$2,625,000500,0000.07%
Other shareholders
MOONLAKE IMMUNOTHERAPEUTICS shareholders Q2 2022
NameSharesValueWeighting ↓
BVF INC/IL 21,751,284$1,239,823,18833.43%
Cormorant Asset Management, LP 8,142,100$464,099,70027.07%
Ally Bridge Group (NY) LLC 183,105$10,436,98512.25%
Finepoint Capital LP 331,416$18,890,7129.41%
Ghost Tree Capital, LLC 330,000$18,810,0006.19%
5AM Venture Management, LLC 313,210$17,852,9705.14%
Ghost Tree Capital, LLC 250,000$14,250,0004.69%
MPM BioImpact LLC 294,190$16,768,8304.48%
Integral Health Asset Management, LLC 500,000$28,500,0003.95%
Altium Capital Management LP 88,000$5,016,0002.62%
View complete list of MOONLAKE IMMUNOTHERAPEUTICS shareholders